Additional AUD$10 million will support MMV’s mission over the next 3 years
MMV welcomes the announcement of AUD$10 million as core investment over the next 3 years to support its work to discover, develop and deliver new antimalarial medicines. This follows a previous grant of AUD$2.5 million in 2013-14.
Dr David Reddy, CEO of MMV, welcomed the Australian government’s commitment. “MMV is grateful for this generous contribution from Australia. This continued support represents a belief in MMV’s proven ability to develop and deliver affordable and effective antimalarials for the world’s most vulnerable people. It also underlines Australia’s acute understanding of the urgent need for novel medicines in the Asia-Pacific region where resistance to the current gold standard antimalarial is emerging.”
Almost half of the world's population is at risk of malaria. It kills over 584,000 people a year, 75% of whom are children under the age of 5. Working in partnership with MMV and the international science community, Australian scientists have made and continue to make a significant contribution to the discovery and development of new drugs and tools to cure and prevent this deadly disease. With the emergence of resistance to the current gold standard antimalarial drugs in S.E. Asia, the need for new antimalarials has become more urgent than ever.
The Australian government’s support of MMV reflects its commitment to the goal of eliminating malaria in the Asia-Pacific region by 2030. It also reflects the Australian government’s commitment to innovative ways to improve health in the region, including through the development of new medical technologies.